Source: Eur Respir Rev, 29 (156) 190068; 10.1183/16000617.0068-2019
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Sheylan D. Patel, Taylor R. Bono, Steven M. Rowe, George M. Solomon. CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways. Eur Respir Rev, 29 (156) 190068; 10.1183/16000617.0068-2019

Member's Comments

No comment yet.

Related content which might interest you: Genomically-guided therapies: a new era for cystic fibrosis Source: Virtual Congress 2020 – European Reference Network for rare lung diseases (ERN-LUNG): acting for improved cross-border management of rare diseases Year: 2020 Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung Year: 2012 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Hypoxia and sterile inflammation in cystic fibrosis airways: mechanisms and potential therapies Source: Eur Respir J 2017; 49(1): 1600903; DOI: 10.1183/13993003.00903-2016 Year: 2017 Cystic fibrosis: prospects for therapy of some class 1 mutations Source: Annual Congress 2007 - Cystic fibrosis: will the new biology deliver? Year: 2007 Treatment of interstitial lung diseases: current approaches and future directions Source: Virtual Congress 2021 – Interstitial lung diseases: from disease mechanisms to novel treatment options Year: 2021 Gene therapy for cystic fibrosis: successes and challenges Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=79 Year: 2006 A European regulatory perspective on cystic fibrosis: current treatments, trends in drug development and translational challenges for CFTR modulators Source: Eur Respir Rev, 27 (148) 170124; 10.1183/16000617.0124-2017 Year: 2018 New insights into the pathophysiology of lung disease in cystic fibrosis patients Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=1 Year: 2006 Current concepts: host–pathogen interactions in cystic fibrosis airways disease Source: Eur Respir Rev 2014; 23: 320-332 Year: 2014 ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies Source: Eur Respir J, 56 (6) 2000946; 10.1183/13993003.00946-2020 Year: 2020 Novel therapeutics for cystic fibrosis Source: ERS Webinar 2020: Novel therapeutics for cystic fibrosis Year: 2020 Update on new treatments for cystic fibrosis Source: Virtual Congress 2020 – Updates in cystic fibrosis Year: 2020 Recent developments in the management of Cystic fibrosis Source: International Congress 2017 – State of the art session: "Paediatric" Year: 2017 Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - MP7 - Targeting airway inflammation in asthma: current and future therapies Year: 2009 Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - PG13 Asthma: pathology and treatment Year: 2009 The need for lung transplantation in cystic fibrosis (CF) in the era of new treatment Source: Virtual Congress 2020 – Lung transplantation in the era of new drugs Year: 2020 Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy Source: Breathe, 17 (4) 210112; 10.1183/20734735.0112-2021 Year: 2021 Pathophysiology of CF and CFTR directed therapies Source: ERS course 2015 Year: 2015